due rapid widespread develop dna vaccine enter variety human clinic trial various disease include cancer revid well tower excel safety profil prove advantage mani combine first phase second save time money clear result obtain require much improv antigen express delivery method make suffice effect clinic similarly admit strategy require active immune poorly immunogen tumor antigen engine vaccine design manipul present process pathway one import aspect easily hand technology sever approach investing codeliveri immunomodulatori molecule safe rout administer primeboost regimen break immunosuppress network meghan adopt align cell prevent immune cell function combine single enhance efficacy immunogen apply complete onto tower platform substantial review salient topic go basic research value metres studi also discus 